Whatever HHS officials envisioned for the first day of open enrollment on the health insurance exchanges, they surely didn't expect to face it with more than half of the department's employees furloughed.
Whatever HHS officials envisioned for the first day of open enrollment on the health insurance exchanges, they surely didn't expect to face it with more than half of the department's employees furloughed.
But that scenario began to play out as the complex launch coincided with the nation's first government shutdown in 17 years after Republicans refused to pass a temporary spending measure without also eliminating or delaying core provisions of the 2010 healthcare law.
“Shutdown or no shutdown, we're ready to go start enrolling people tomorrow,” HHS Secretary Kathleen Sebelius told healthcare reporters at HHS headquarters on Monday. Individuals can shop for coverage in the exchanges at www.HealthCare.gov starting at 8 a.m. ET Tuesday. The secretary added that HHS also plans to “turn up the volume” on its educational efforts in the next six months through television ads, traditional and social media, and in-person conversations.
Read the full story here: http://bit.ly/16dePUb
Source: Modern Healthcare
Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD
May 9th 2025Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen